PRIMEVIEW CRANIOPHARYNGIOMA


Craniopharyngiomas (CPs) are rare embryonic tumours that arise along the craniopharyngeal duct in the skull. Although survival is high, the close anatomical proximity of CPs to the optic chiasm, hypothalamus and pituitary gland can impair quality of life.

QUALITY OF LIFE

Hypothalamic damage is a major consequence of CPs, either preoperatively (owing to adhesion of the tumour to the hypothalamus), or postoperatively (as a result of surgical and/or radio-oncological treatment).

MECHANISMS

There are two histological subtypes of CP, namely adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP). ACPs are driven by somatic mutations in CTNNB1 (encoding β-catenin). Mouse models suggest that expression of oncogenic β -catenin in precursor cells that express the transcription factor SOX2 results in the formation of cell clusters that exhibit a pro-tumour senescence-associated secretory phenotype. This phenotype includes secretion of various factors, including growth factors, cytokines and chemokines, which induce transformation of a neighbouring cell to become tumour-initiating, and fuel tumour growth once initiated. By contrast, PCPs frequently harbour somatic BRAF^{V600E} mutations that result in the activation of the MAPK signalling pathway, but the causative effect of these mutations has not yet been demonstrated. However, the BRAF^{V600E} mutation may transform cells that express SOX2 to initiate tumour development.



Disturbances to the hypothalamic-pituitary axis affect secretion of growth hormone, gonadotropins (namely, luteinizing hormone and follicle-stimulating hormone), thyroidstimulating hormone and adrenocorticotropic hormone.

EPIDEMIOLOGY

diagnosis of 40-55 years).

in satiety regulation, energy expenditure and central sympathetic output in those with hypothalamic damage typically result in morbid obesity that is usually unresponsive to conventional treatment efforts, such as lifestyle modifications

Impairments

In adult-onset disease, reduced sexual function (due to gonadotropin deficiency) and hyperprolactinaemia are major symptoms

The type

and extent of visual impairment

varies depending on

how distorted the

optic chiasm is by

the tumour

OUTLOOK

CPs constitute 1.2-4.6% of all intracranial Alongside infrastructural improvements to tumours globally. ACPs affect all age groups ensure diagnostic and therapeutic quality (but have a bimodal peak incidence in children globally, efforts are underway to develop aged 5-15 years and adults aged 45-60 years) better treatments for CP. For example, targeted therapies in PCPs habouring BRAF^{V600E} mutations and are the more common subtype. PCPs are mostly restricted to adults (mean age at are being tested and cytokine inhibition is being considered in ACP.

<u>nature</u> disease REVIEWS PRIMERS

For the Primer, visit doi:1038/s41572-019-0125-9

DIAGNOSIS

Patients with CP typically present with features of increased intracranial pressure (for example, headache), visual impairment and endocrine abnormalities (for example, diabetes insipidus). Typically, patient history, biochemical assessment and detailed neuroimaging can confirm a diagnosis. On imaging, ACPs can be described using the '90% rule' — in which ~90% of tumours are predominantly cystic, ~90% show prominent

Hypothalamic dysfunction is also a risk factor for impairments in body image, social functioning and physical ability; longterm neurocognitive complications problems affecting attention and executive function.

calcifications and ~90% take up contrast media in the cyst walls. PCPs are more frequently uncalcified, 'solid' and usually lack cysts. The major differential diagnoses

for CPs include low-grade gliomas and germ cell tumours.

MANAGEMENT

Treatment options include surgery or radiotherapy or, more commonly, a combination of the two. However, surgery as a sole treatment is only appropriate for tumours that can be completely resected without neurovascular injury or visual impairment. In children in particular, such an approach must be carefully planned. For CPs that have invaded the hypothalamus, partial resection and radiotherapy may be the best option for treatment.